Following USPTO (
US15/751,170), and Taiwan (
TW201705973A; 105125583), Eyesiu also received the “Decision to Grant” letter from the Federal Service for Intellectual Property (ROSPATENT) of Russia for its patent application ““Pegylated lipid nanoparticle with bioactive lipophilic compound”, while the application is pending in the EU, China, South Korea, Japan and India. The granted claims for the solvent-free and serum-stable nanoparticles comprise two or more phospholipids and at least one of an acylethanolamide (such as the endocannabinoids 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide), oleoylethanolamide (OAE), or palmitoylethanolamide (PEA)) and a macrolide (such as tacrolimus, sirolimus or cyclosporine A), wherein the nanoparticle has a surface comprising a water soluble polymer (such as PEG).
“Being rewarded with an issued patent by Russia, Taiwan and the US for the core of our invention is very gratifying and a validation of Eyesiu’s series of related therapeutics and nutraceutical products in development and available on the market”, comments Dr. Pieter J. Gaillard, founder and CEO of Eyesiu. “This third allowance in a row of Eyesiu’s patent application, now by ROSPATENT, with broad and commercially relevant claims deepens our belief that the technology will also obtain similar product protection in the other geographies where the application is currently pending”, Gaillard adds.
Use of CsA in COVID-19
Of special note is that at the start of the first wave of COVID-19 in Europe, Gaillard already wrote a series of blogs in which he explained how in the immediate term and by using this innovative solvent-free and serum-stable nanotechnology, the existing medicines such as CsA for patients, and lipid-based formulations of food supplements such as PEA for consumers, can already help to combat against COVID-19, the latter by providing targeted support for a healthy diet and lifestyle. See these blogs
here
(in Dutch about PEA), and
here
(in English about CsA and PEA), and
here
(about the PEA hypothesis). Meanwhile, on 15 October 2020, a first study was published in a
Lancet article
in which
CsA in more than 600 patients with Corona showed that administration of this drug reduces the risk of death by 81%. These promising data were generated by a team at a Spanish hospital in Madrid, who analysed the records of 607 severe COVID-19 patients admitted in March and April during the first wave, when they were treated with one or more potential helpful drugs in critical cases, including
CsA, glucocorticoids, tocilizumab, HIV antivirals, and hydroxychloroquine. In this study,
CsA was the only drug that clearly reduced deaths
(36 (14%) of the 253 patients who received CsA died, whereas in a closely matched comparison group 105 (almost 30%) of 354 patients who did not get the drug died). Such encouraging outcomes definitely warrant further investigations on the use of CsA in severe COVID-19 patients, while CsA's tolerability may be further improved by Eyesiu's nanotechnology and readily scaled up to widespread use.
Eyesiu’s therapeutics and nutraceuticals
Eyesiu has developed therapeutics, in pre-clinical stage, targeting a wide range of indications in neurology, ophthalmology, dermatology and pulmonology. The company has also developed nutraceuticals (food supplements) that support its users to maintain pain-free and healthier brain, eyes, lungs, skin and/or hair: the first one is a spray bottle with PEA, comprising a lipid-based sublingual, skin and mouth spray formulation for convenient, effective, fast and sustained delivery, and is for sale through Eyesiu’s health care division (Eyesiu Care) via
www.PEArlboost.com
About Eyesiu Medicines BV and Eyesiu Care
For further information, please contact
Eyesiu Medicines BV | Pieter J. Gaillard | info@eyesiu.com